Guidance language shifted to highlight mid-2025 catalysts for EYLEA HD, including the prefilled syringe launch and label ...

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing a supplemental biologics license application ((sBLA)) for its eye disease drug Eylea HD injection, 8 mg, to expand its ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its. TARRYTOWN, N.Y., April 18, 2025 (GLOBE ... which is the maximum dosing interval currently indicated in the label).

Sales of Eylea HD have likely surged in the to-be-reported quarter on strong demand. ... The recent label expansion of the drug in the COPD indication has likely boosted sales further.

U.S. sales of Eylea HD increased by 54% year over year to $307 million in the period. ... Furthermore, Eylea HD could potentially earn label expansions, helping to mitigate Eylea-related losses.

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response ...

Guidance language shifted to highlight mid-2025 catalysts for EYLEA HD, including the prefilled syringe launch and label expansions. In Q3, management only referenced ongoing adoption efforts.